Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545623 | 0.87 | CAMK1D (0.41) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL23113552 | 0.86 | POLB (0.39) | HDAC3HDAC6MAPTRXRARXRB | |
| SCHEMBL5475672 | 0.81 | RAF1 (0.39) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL5220073 | 0.78 | GAA (0.50) | MAPTCES2ALDH1A1P2RX1LMNA | |
| SCHEMBL14493273 | 0.77 | TSHR (0.41) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL2338206 | 0.76 | GABRA1 (0.44) | HDAC3HDAC1HDAC6MAPTRXRA | |
| SCHEMBL529254 | 0.73 | EPHX2 (0.42) | MAPTALDH1A1PDE2ALMNAKDM4E | |
| SCHEMBL130383 | 0.73 | TSHR (0.56) | MAPTCES2ALDH1A1GAANR2E1 | |
| SCHEMBL17713890 | 0.72 | P2RX1 (0.42) | MAPTCES2RXRARXRBALDH1A1 | |
| SCHEMBL12475154 | 0.72 | GPR35 (0.56) | MAPTIKBKEALDH1A1GPR35P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530193-B2 | Kinase inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2022-12-20 | — | — | US | disclosed |
| EP-3793996-A1 | KINASE INHIBITORS | The University of Manchester (GB) | 2021-03-24 | — | — | EP | disclosed |
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2020-02-18 | — | — | US | disclosed |
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-05-16 | — | — | US | disclosed |
| US-10208038-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2019-02-19 | — | — | US | disclosed |
| US-20180282326-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2018-10-04 | — | — | US | disclosed |
| EP-3013798-B1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEIGENE LTD (KY) | 2018-06-27 | — | — | EP | disclosed |
| US-9920055-B2 | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2018-03-20 | — | — | US | disclosed |
| US-20170233391-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2017-08-17 | — | — | US | disclosed |
| US-9670203-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-20160368914-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2016-12-22 | — | — | US | disclosed |
| EP-3013798-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BeiGene, Ltd. (KY) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014206343-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
| EP-1957460-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368914-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | HDAC3 1597/4885HDAC1 780/4885HDAC2 1364/4885 |
| US-20180282326-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | HDAC3 1597/4885HDAC1 780/4885HDAC2 1364/4885 |
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | HDAC3 1597/4885HDAC1 780/4885HDAC2 1364/4885 |
| US-11530193-B2 | Kinase inhibitors | CAMKK2, CAMK1, CAMKK1 | HDAC3 860/4885HDAC1 1101/4885HDAC2 426/4885 |
| US-20170233391-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | HDAC3 1597/4885HDAC1 780/4885HDAC2 1364/4885 |
| US-10208038-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BRAF, RAF1, ARAF | HDAC3 1597/4885HDAC1 780/4885HDAC2 1364/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | HDAC3 802/4885HDAC1 599/4885HDAC2 626/4885 |
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BRAF, RAF1, ARAF | HDAC3 1597/4885HDAC1 780/4885HDAC2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.